This review summarizes the studies on the cognitive side-effects of two important antiepileptic drugs: phenytoin and carbamazepine. A large literature database was compiled through the DIMDI computer database and the inspection of recent reviews. Only scientific articles published in peer-reviewed journals during the last 25 years were selected. Of the 358 potentially relevant papers on cognitive effects of AEDs, a total of 16 studies have been found that have studied both carbamazepine and phenytoin. After excluding studies with designs that do not permit valid inferences regarding the cognitive effects of AEDs, only five studies remained.
INTRODUCTION
During the last 25 years, a considerable number of studies has been published on the topic of cognitive side-effects of antiepileptic drugs (AEDs). At first glance these cognitive side-effects seem less dramatic than e.g. the acute dose-related effects or the idiosyncratic reactions to drugs. Nonetheless, a number of studies have claimed that drug-induced cognitive impairment may have a much greater impact on daily life function than had hitherto been suspected 1-9.
The cognitive side-effects represent the longterm outcome of the chronic toxicity of the AEDs rather than the acute reaction to drugs. This may contribute to the impact on daily life functioning, especially in refractory epilepsies, as the effects may increase with prolonged therapy l°.
As a consequence, cognitive side-effects now represent a major issue in clinical assessment and in studies on new antiepileptic drugs. Fortunate as this is, the literature still shows serious controversies about type and severity of drug-induced cognitive impairment, even in recent and well-controlled studies. These controversies are due to e.g. differences between the studies with respect to the type of subjects investigated and the design used to detect the drug effects. In this review we will concentrate on two most commonly used (and studied) AEDs phenytoin (PHT) and carbamazepine (CBZ) . While evaluating the reports on PHT and CBZ, and their conflicting results, we will consider certain basic methodological issues with general implications for the assessment of drug-induced cognitive impairment.
Phenytoin was first introduced for treatment in 1938 and was long (together with phenobarbitone) the universal treatment for epilepsy.
Carbamazepine was not introduced until the 1960s, although the drug was used as an antidepressant at an earlier stage. The structure is similar to other tricyclic antidepressants. In contrast with PHT the administration of CBZ is mostly in multiple dose form TM 12 One of the most authoritative reviews of the recent years 2 gave the following table (Table  1) , summarizing the results of a large number of studies on effects of several AEDs on general behaviour and on cognitive function. The suggestion from this summary, but also from other reviews 1-9' lo. 12,14 is clearly that PHT is more harmful to cognitive function than CBZ. This conclusion came back into debate recently as some studies ls-19 failed to reproduce the cognitive side-effects of PHT when serum concentrations were sufficiently controlled. These studies suggest that some of the reported differences between CBZ and PHT actually may have been due to an artefact, i.e. differences in drug concentration. Moreover, some studies suggested that subject selection bias may have influenced the results, as there is evidence that, at least in some countries, phenytoin may be given to other types of patients than carbamazepine. PHT is cheaper and it is considered a 'simple drug', because it can be given once a day 14'2°-23. Observed cognitive differences between groups after exposure to PHT and CBZ may thus simply reflect prior differences rather than drug effects. This implies that a baseline-measurement is crucial to reach valid conclusions about drug effects, at least in studies where randomized treatment allocation is not feasible. Finally it is suggested that the apparent adverse effects of PHT on cognitive functions may actually have been due to a contaminating factor: motor speed. In one study 19 motor slowing appeared to be the only factor that discriminated between PHT and CBZ. As almost all cognitive tests use motor output, 'periph-
eral' motor effects may erroneously have been interpreted as 'central', cognitive effects.
A critical review of the existing literature on PHT-CBZ comparisons is therefore useful, both for future research and for the proper interpretation of existing data, a highly relevant issue to clinical practice.
IDENTIFICATION OF RELEVANT STUDIES

Literature-search
As a first step in identifying relevant studies, the DIMDI computer-database was accessed through the keywords AEDs and antiepileptic drugs. Next, a number of reviews 1-14'2°-23 on the same topic were checked for additional references. These papers were screened for information about cognitive side-effects of AEDs. The resulting literature base comprised 358 potentially relevant papers. Then the inclusion criteria given in Table 2 were applied. These criteria reflect both our clinical and theoretical interest. Included studies should be readily accessible, and allow the readers to judge the validity of the results; abstracts, for example, usually do not provide sufficient detail. The target population is the epilepsy patient, receiving long-term AED treatment. AED treatment in other groups is associated with complicating interactions between condition and therapy. An exception was made for studies in healthy volunteers, on the assumption that such studies might suggest hypoth-eses worth further exploration in epilepsy. The constraint on publication date was set fairly arbitrarily at 25 years ago. Studies after that date were all done in a time when serum level monitoring and modern cognitive tests had come into widespread use. After application of these criteria, a database of 73 articles remained. A review of this database will be presented elsewhere. A last criterion was that only those studies were included that examined both PHT and CBZ within the same investigation. This criterion was formulated because of the large variation between studies with respect to type of cognitive tests, number of tests and the 'cognitive models' to interpret the test results. To guarantee comparability of results, inclusion of a study only followed when both type of AEDs were examined with the same set of tests. After application of these criteria, a database of 16 articles 15-17"24-:~7 remained.
In weighing the evidence from these studies, the approach taken here is primarily to evaluate their design and analysis, disregarding studies that contain certain basic deficiencies that render them uninformative with regard to cognitive AED effects, because they fail to rule out too many plausible alternative explanations. The emphasis in this review on aspects of methodology is due, as some designs are arguably not sufficient for permitting reasonably valid inferences regarding the cognitive AED-effects. The problems examined here are not minor annoyances: their impact on the validity of the conclusions drawn is such that a useful AED, not harmful to cognitive functioning might look bad, while genuine adverse cognitive effects might be missed.
One example may illustrate the relevance of methodological and statistical issue. Authors may wish to emphasize 'no effect' findings, particularly if these are in line with the research hypothesis that a certain AED has no adverse cognitive effects. In contrast to studies in other areas, non-significant results are seen as good news here as they represent the absence of cognitive side-effects. This conclusion lacks meaning, however, unless the a-priori probability of obtaining a significant result ('the power') is sufficiently high (80c~ being a conventional value). In other words, the study should have been able to detect genuine impairment and non-significance should not be due to insufficient power. The power decreases especially if small samples are used, or if the effect size, i.e. the magnitude of the cognitive effects under study, is small. In order to achieve an 80c~ chance of detecting small, medium and large differences {0.20, 0.50 and 0.80 standarddeviation, respectively in line with the convention proposed by Cohen :~s) between two independent means, the necessary number of patients per group, at a 5e;~ significance level, is 393, 64 and 26, respectively. Nonetheless, limited sample sizes (20 or lessl are used in the majority of studies {column 3 in Tables 3 and  41 . By consequence, these studies can only detect cognitive effects of such magnitude that they would presumably be obvious to the clinician, even without psychological tests. And yet, conclusions that state a 'no effect' are readily found in literature, even in lowpowered studies with a minimal chance of finding anything but unrealistic massive effects. With 'no-effect' claims it is therefore worth checking whether they might not simply reflect inadequate power. Thus, the studies published in this field are first examined with respect to formal characteristics relevant to valid inference making about cognitive sideeffects. With only high quality data to go on, the last section of this review attempts to draw conclusions in which some confidence can be placed. Tables 3 and 4 give a general summary of studies that were found in our literature search on cognitive side-effects of CBZ and PHT.
DESCRIPTION OF THE INVESTIGATED STUDIES
The studies will be summarized in Tables 3  and 4 in terms of five relevant features: ( 11 the treatments under comparison; (21 the n umber of subjects In) in each treatment condition, including untreated controls; I31 the drop-out rate that gives an indication as to whether a selection artifact might have developed during the trial; (4) the number of cognitive variables used as outcome measures, that gives an indication of the possible scope of the study with respect to cognitive functioning; (5) the time on AEDs under study is an important consideration in judging to what extent the results apply to chronic AED use.
Study 1
The first study 16 mentioned in Table 3 is the only normal-volunteer study in which CBZ and This refers to the duration of the experimentally changed AED treatment c.q., the continuous medication interval studied, or the duration of AED therapy prior to assessment in cross-sectional studies.
:~ E denotes epileptic controls; other controls are non-epileptic controls. n.a. = not applicable; ? = information insufficient, ambiguous or lacking. 6/12 months PHT/CBZ/PHB 15 --+28q 7 9 months *plac = placebo. Individual AEDs are in bold print: CBZ = carbamazepine; OXC = oxcarbazepine; PHT = phenytoin; VPA = valproate; PHB = phenobarbital. t This refers to the duration of the experimentally changed AED treatment c.q., the continuous medication interval studied, or the duration of AED therapy prior to asessment in cross-sectional studies. $ In the withdrawal studies the period refers to the total follow-up period (withdrawal of the drug and follow-up after withdrawal}. ? = Information insufficient, ambiguous or lacking.
PHT was studied. CBZ and PHT is given during a month to normal volunteers in a randomized cross-over design.
A few comments have to be made when assessing the value of the results of any normal-volunteer study on cognitive effects of AEDs. This type of study has some clear advantages. The problems of the intervening contribution of seizure-related variables on cognitive function is absent and manipulations of drug and dose are not limited by clinical considerations. A clear disadvantage is that the period of drug exposure is mostly restricted. There is evidence that in most AEDs some 'early' cognitive side-effects may develop, only during a short period, i.e. during the first few days or weeks of drug exposure. After this period normalization occurs, possibly due to the development of so-called positive tolerance 39. Although little is known about how tolerance to the cognitive effects of AEDs develops, a failure to control the period of drug exposure may lead to overestimation of the negative effects of drugs on cognition 2°'2~. This important point has to be taken into account in studies with healthy volunteers who are typically given AEDs during a few weeks at most, long-term studies not being feasible. Our examination of the 14 normal-volunteer studies that were carried out to assess the cognitive effects of AEDs revealed that the majority of these studies used a fairly short period of drug exposure, often no longer than 1 day. The study by Meador et al. 16 is an exception as both AEDs were given during a period of one month.
Study 2
In total we found 20 polytherapy studies on cognitive effects of AEDs. Only one study 36 met our criterion that the study should investigate both PHT and CBZ. Polytherapy is the most common treatment in refractory epilepsies but it introduces certain complications in identifying the exact cause of observed cognitive changes. Interactions between antiepileptic drugs became evident soon after routine measurement of serum levels came into practice. Such interactions can alter therapeutic efficacy and thus, conceivably, cognitive functioning. Moreover polytherapy is typically given to patients suffering from refractory epilepsy, and the threat of a 'seizure confound' is thus always serious. 'Seizure confound' refers to a major validity concern: the separation of seizure effects from 'genuine' AED-effects.
The study by McKee et al. 36 is an 'add-on study', where a new drug is introduced into a polytherapy regime. In this type of study the seizure confound is even stronger and the results on cognitive tests are a potpourri of positive and negative seizure effects, AEDeffects and drug-drug interactions that can never be disentangled. It is therefore impossible to use this type of study for inferences about differential-cognitive side-effects of PHT/CBZ.
Studies 3-5
The studies numbered 3-5 in Table 3 are combined under the heading 'monotherapy studies 99 providing insufficient information for evaluation '17"29"35 . This illustrates an important point that we want to make here. Some papers evidently do not provide the information to enable the reader to evaluate the appropriateness of the methods and the reliability and validity of the results. For example, certain articles fail to give the number of subjects studied, do not report inferential statistics to support the conclusions, or mention only those cognitive variables yielding significant effects. One is thus forced into the unfortunate position of either accepting results uncritically, or specifying certain minima with respect to the methodological/statistical information provided, that must be met before evaluation is possible. We chose the latter option. In this review we employ only the criteria: 'numbers of patients' and 'number of cognitive variables'. Evidently, these data are essential to evaluate the statistical power of the study and, consequently, the validity of the reported results, especially in the case of 'no-effect' reports. All three studies, mentioned under this heading in Table 317 '29'35 fail to meet these presentation minima and are thus considered elusive to evaluation due to insufficient information.
Studies 6-10
The studies, numbered 6-10 in Table  326 -2s'3°'34 are monotherapy studies that have a specific design in common, the post-test-only design, that also needs some general comments. Due to the lack of pretest observations in this 'one-shot case design' there is no way of knowing whether the treatment is related to any kind of cognitive change. Posttest differences can be attributed either to a treatment effect or to various selection differences between PHT/CBZ groups. The plausibility of such selection differences renders this design uninterpretable. Note that it is a different matter with randomized experiments where pretests can be dispensed with, random assignment insuring the comparability of the treatment groups. In a post-test-only design without random treatment allocation, one can never be certain that some variable that has been overlooked will not bias the outcome of the study. Control on selection bias is thus essential in any non-randomized study and can only be achieved by using a pre-and post-test design.
A concrete example of a validity threat in this design is found in the study by Andrewes et al. 26 The authors conclude that PHT shows an overall trend towards poorer performance on several cognitive tasks when compared to CBZ. This study is frequently cited as evidence for the cognitive side-effects of PHT. However, as Table 3 shows, the period of drug exposure is different between the two groups (3.6 years for CBZ and 5.8 years for PHT). It is conceivable that longer drug exposure in itself, regardless of type of drug, leads to the differences between the investigated groups. Thus, the results of such studies do not allow valid inferences about cognitive side-effects of AEDs as their design is generally uninterpretable 4°. The monotherapy studies numbered [11] [12] [13] [14] [15] [16] in Table 415 '24"25'31-33 potentially allow valid inferences about the cognitive effects of PHT and CBZ. At least they meet the minimal requirements that were formulated in the foregoing:
--a period of drug exposure that allows the generalization of the results to the 'regular' epilepsy patient on long-term AED therapy; --minimal standards for presentation of the results; --a design that allows us to distinguish the cognitive effects of AEDs from factors such as selection bias (thus excluding the posttest-only design); --a type of treatment that allows interpretation of specific effects of PHT and CBZ (thus excluding polytherapy studies).
Seven studies meet these criteria. However, some of these studies have such problems in design and analysis that inferences about cognitive side-effects of AEDs are impossible, if only because alternative explanations cannot be ruled out. We do not intend to give a complete description of these studies, but merely comment on the factors that prevent the interpretation of the study results. practice effect. Thus, the validity of the results from this type of study largely depends on the extent to which retesting effects are controlled. Retesting effects are dependent on factors such as the type of tests and the number of retests. Gallassi and coworkers use four retests and at least three of the tests are known to be extremely sensitive to such retesting effects: 'Raven Progressive Matrices', a Visuo-Motor Test and a Verbal Learning Task. Apparent improvement produced by retesting may thus erroneously be interpreted as evidence for the elimination of cognitive side-effects. In the Gallassi studies a'~'~3, however, the control subjects are only tested once. Thus it would not be clear whether any differences between groups were due to the removal of the treatment or to differences in the frequency of measurement.
Study 13
The Swedish 'Holmfrid study "~ also uses a withdrawal design: assessing patients on monotherapy PHT or CBZ, followed by reassessment after complete withdrawal of the medication. Practice effects are controlled by the use of a control group that follows the same testing schedule as the experimental groups.
Study 14
One of the pioneer studies in this field is the study by Dodrill and Troupin 3~ comparing CBZ with PHT in a randomized cross-over design. Patients are assessed at the end of a four-month treatment period. The study gives data on relative effects of the drugs, i.e. differences between PHT and CBZ. The patients have not been tested pre-treatment or compared to an untreated control group.
Studies 11 and 12
The studies by Gallassi and coworkers "J' 2":33 use an interesting design: patients are tested on monotherapy and retested after removal of the medication. The assumption in this 'withdrawal design' is that reversible side-effects are demonstrated by an improvement after a drug is stopped. A point to be made here is that other factors can also cause such improvement, one of the most obvious being the retesting or
Study 15
The study by Aikia et al. 24 uses a randomized double-blind parallel group design. Patients are assessed before the treatment is started, and then given either of the two AEDs. The study does not use carbamazepine but the related drug oxcarbazepine. The absence of the metabolite epoxide m'~ in oxcarbazepine, that may possibly cause the side-effects in carbamazepine treatment, may reduce the generalizability of the results towards ordinary carbamazepine treatment. Other limitations of this study will be discussed in the next paragraph.
Study 16
The study by Meador et al. 5 is a randomized double-blind triple cross-over design comparing CBZ with PHT and PHB in 15 patients. The study lacks a no-treatment reference: the patients are not tested during a pretreatment phase and the study does not use an untreated control group. Of these studies, the two Gallassi studies 32'33 have such serious threats to validity that the results can not be safely interpreted. The results of the remaining studies plus the normal volunteer study ~6 are discussed in detail in the next section.
RESULTS OF THE INVESTIGATED STUDIES: INFERENCES ABOUT THE COGNITIVE SIDE-EFFECTS OF PHENYTOIN VS CARBAMAZEPINE
In this section we summarize the results of those studies that do allow interpretation of the data. Table 5 summarises these studies.
Study 1
In the normal volunteer study ~6, two of the 20 drug-drug comparisons between PHT and CBZ yielded statistical significance: Finger tapping favoured CBZ and Stroop favoured PHT. However, as the study used separate Ftests, this may well represent a chance finding, a point that is recognized by the authors.
This illustrates a more general issue. In most studies multiple measures are used to capture cognitive AED effects, and then tested independently for significance. However, the probability of falsely concluding that one or more significant effects exist, increases as a function of the number of statistical tests performed, and a certain proportion of the tests will be significant by chance. Thus, with a conventional 5% significance level, one may expect that 1 in 20 cognitive measures will yield a significant effect by chance alone. Failure to recognize this problem may lead to 'fishing' for significant findings, some of which may be 'false positives', whereas measures failing to yield significant effects may not even be mentioned as having been administered '7°.
The comparison of CBZ or PHT with a 'nondrug condition' raises a problem regarding the validity of their conclusion that 'no differences exist between the two drugs and the non-drug condition'. The study does not employ an untreated control group but uses two non-drug conditions: the subjects are tested at baseline (before the first drug is given) and after treatment and withdrawal of the second drug. The scores of the two non-drug conditions are then averaged; this score is compared with the two drug conditions. This procedure may over-or under-estimate drug-effects, as the second baseline is the fourth consecutive measurement and is thus maximal biased by retesting effects conceivably leading to exaggerated nondrug scores. On the other hand, the study is not conclusive as to whether both drug conditions (second and third assessment) are also affected by retesting effects. Only an independent nondrug group, tested and retested at the same intervals could have controlled for these retesting effects.
We must therefore conclude that this study only gives interpretable data as far as the drug-drug comparison is involved. This comparison did not yield significant differences between PHT and CBZ above chance level. As the number of subjects in this study is rather small (n = 21), this 'no difference' finding is not particularly meaningful without a formal power analysis, showing that even small or medium sized effects could have been detected. At best we may infer from these results that massive differences were not present.
A.P. Aldenkamp & J. Vermeulen of this study, causing a failure to detect genuine impairment. We therefore evaluate the evidence from this study as inconclusive.
Study 2
In the original study by Dodrill and Troupin ~' impairment of attention and problem solving in PHT (relative to CBZ) was reported, but 14 years later the authors reanalysed their data TM and argued that no differences between PHT and CBZ remained, after removing high PHT serum levels. This procedure of course resulted in smaller sample sizes, i.e. when removing patients with serum levels >40~tg/ml, the sample size decreased from 40 to 29, with the removal of serum levels >30 ~xg/ml, a sample of 15 patients remained. The original statistical differences were lost with these smaller sample sizes. A formal power analysis to support the meaning of this no-difference (true absence of differences, or an effect of insufficient power} was not presented. Again, at best, we may infer from these results that extreme differences between PHT and CBZ were probably not present.
Study 3
The study by Aikia et al. 24 seems to reconfirm the absence of differences between the PHT and CBZ in a different patient group (seizurefree patients vs refractory patients in the former study by Dodrill and Troupin) with PHT serum levels of about 50% lower than in the study by Dodrill and Troupin. The study reports both the absence of PHT-CBZ differences and drug-non drug differences, suggesting a complete absence of cognitive drug effects.
We have pointed out in the foregoing that the results of this study must be interpreted with caution as the study does not compare phenytoin with carbamazepine but with the related drug, oxcarbazepine. An additional problem is the limited sample size (14 vs 15), combined with a 20% drop-out rate in this study. An example of the effect of the small sample size is that even a difference between the groups of approximately one standarddeviation at pretest (an effect size that is generally considered as 'large 'as} still does not yield statistical significance. Thus the absence of effects may simply reflect the limited power
Study 4
The Swedish withdrawal study 25 reported no significant differences between CBZ and PHT in children. In addition, no differences were found with untreated controls in both conditions (during treatment and after withdrawal}. This suggests the absence of cognitive effects of both PHT and CBZ.
However, the group of patients on phenytoin is probably too small to render a sufficient level of statistical power (n --10). Valid comparisons between PHT and CBZ and between PHT and a non-drug condition are therefore not possible. The data only allows valid inferences about differences between CBZ (n = 56) and the nondrug condition (n = 83). This comparison does not yield significant differences.
Study 5
The final study that will be discussed here is the study by Meador et al. 15 The study compares the cognitive effects of PHT with CBZ but lacks an absolute reference: the patients are not tested during a pretreatment phase and the study does not use placebo control or an untreated control group. The overall conclusion of the study, i.e. 'no differences between the drugs' can only be given limited credit. The study uses a small sample (15 patients; seven cognitive variables} that only allows to detect massive cognitive changes.
CONCLUSIONS
A disappointing number of studies pass criteria of design, methodology and statistical analysis that are in line with common scientific conventions 4°. From a database of 358 papers on cognitive effects of AEDs, a total of 16 studies have been found that have studied both CBZ and PHT. After the exclusion of the polytherapy studies, post-test only studies as well as studies that could not be evaluated because of the lack of information, only seven studies remained of which five studies potentially allowed valid inferences about the cognitive effects of PHT and CBZ. This necessarily leads us to our first conclusion: our current knowledge about these side-effects is far from complete. The main reason is that most studies fail to meet the criteria for design, methodology and type of analysis that are indispensable for the rather complex studies on cognitive effects of AEDs.
Our current knowledge allows us to draw conclusions about the cognitive side-effects of phenytoin and carbamazepine only with great caution. The summaries that were shown in the introduction and that by and large claim that 'both drugs have an impact on cognitive function, PHT to a larger degree than CBZ ''~ are simply not supported by valid 'high quality' data. The same is true for the overall conclusion in more recent reviews 14'2°'21 that 'drug-induced cognitive effects of these AEDs on cognitive function are probably mild or even negligible'. Table 5 does neither support the first nor the second overall conclusion but rather illustrates a surprising lack of knowledge.
There are three studies that claim evidence that the differences between PHT and CBZ are probably mild or even absent. These studies presumably lack statistical power (given the small sample sizes) and may thus have missed genuine impairment. Apparently, the only information that we have is that the differential impact of PHT and CBZ on cognitive function is not extremely different.
Furthermore, the absence of PHT-CBZ differences obviously does not rule out the possibility that they are not different because they both impair cognitive function to the same extent. This of course is crucial for clinical practice, especially in the light of the new generation of antiepileptic drugs that are or will be marketed in the near future. AEDs such as felbamate, tiagabine, lamotrigine, oxcarbazepine or the new experimental drugs, such as CGP 33.101, gabapentin or topiramate, might be good alternatives when they have the same efficacy, but with fewer side-effects. Regrettably no conclusive and reconfirmed data are available on PHT and CBZ. This implies that we have no ready advice for the clinician. Rather we have to encourage research programmes that investigate these AEDs with a more solid design, and simultaneously screen the new compounds according to the same standards.
For future studies we would strongly recommend that cognitive effects of AEDs would be investigated: --only under monotherapy; --when randomized treatment allocation is not feasible, with a pre-and post-test comparison;
--with a non-drug condition. Which condition needs to be used (placebo, pretreatment assessment or a non-drug control group) depends upon the type of study; --after a prospective power analysis to determine the necessary sample size for the study to make valid 'no-effect' inferences about specific AEDs.
Other more detailed conditions have been summarized elsewhere L4.z°'2~'~'~
